- Previous Close
13.65 - Open
13.60 - Bid --
- Ask 13.50 x --
- Day's Range
13.05 - 13.60 - 52 Week Range
11.10 - 17.55 - Volume
75 - Avg. Volume
22 - Market Cap (intraday)
240.693M - Beta (5Y Monthly) 1.06
- PE Ratio (TTM)
27.77 - EPS (TTM)
0.47 - Earnings Date May 9, 2025
- Forward Dividend & Yield 0.38 (2.95%)
- Ex-Dividend Date Apr 25, 2024
- 1y Target Est
--
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardiac and vascular surgery in the United States, Europe, Asia, and internationally. The company offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and TTFM in a single system for vascular surgery; MiraQ Ultimate that combines TTFM and ultrasound imaging in a single system for cardiac, vascular, and transplant surgery; and imaging probes for intraoperative use. It also provides QuickFit TTFM probes, which is designed to hold the vessel and ensure precise measurements on various types of vessel grafts; Vascular TTFM probes for locking slide mechanism designed to secure the vessel while minimizing the manipulation of fragile or calcified vessels; and Doppler probes that are used to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, the company distributes and sells third party medical equipment. Medistim ASA was founded in 1984 and is headquartered in Oslo, Norway.
www.medistim.comRecent News: MD1.F
View MorePerformance Overview: MD1.F
Trailing total returns as of 4/11/2025, which may include dividends or other distributions. Benchmark is OBX Total Return Index (OBX.OL) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MD1.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MD1.F
View MoreValuation Measures
Market Cap
240.69M
Enterprise Value
227.99M
Trailing P/E
27.94
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.16
Price/Book (mrq)
6.63
Enterprise Value/Revenue
4.92
Enterprise Value/EBITDA
17.38
Financial Highlights
Profitability and Income Statement
Profit Margin
18.67%
Return on Assets (ttm)
15.16%
Return on Equity (ttm)
24.88%
Revenue (ttm)
556.16M
Net Income Avi to Common (ttm)
103.83M
Diluted EPS (ttm)
0.47
Balance Sheet and Cash Flow
Total Cash (mrq)
179.21M
Total Debt/Equity (mrq)
7.87%
Levered Free Cash Flow (ttm)
81.67M